{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-22-000162","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.392041+00:00","generated_at":"2026-06-21T04:39:15.995388+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Veracyte's Global CSO/CMO Giulia Kennedy to depart Dec. 31, 2022","bullets":["Dr. Kennedy will leave Veracyte effective Dec. 31, 2022; separation agreement signed.","Severance includes six months' salary and up to 24 months of COBRA coverage.","She will receive her 2022 annual performance bonus at the corporate achievement level.","Additional $100,000 cash payment in appreciation for her contributions as an early employee."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-22-000162","json":"https://secwatch.observer/filing/0001384101-22-000162.json","markdown":"https://secwatch.observer/filing/0001384101-22-000162.md","text":"https://secwatch.observer/filing/0001384101-22-000162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000162/0001384101-22-000162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000162/vcyt-20221209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:39:15.995388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c40644c240","claim":"Giulia C. Kennedy departed as Global Chief Scientific Officer and Chief Medical Officer at VERACYTE, INC..","evidence_excerpt":"On December 9, 2022, Giulia C. Kennedy, Ph.D, Global Chief Scientific Officer and Chief Medical Officer of Veractye, Inc. (the “Company”), and the Company agreed that she would depart from the Company, effective December 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000138410122000162/0001384101-22-000162-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Global Chief Scientific Officer and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}